What is HC Wainwright’s Estimate for NEUP Q2 Earnings?

Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) – Investment analysts at HC Wainwright issued their Q2 2025 EPS estimates for Neuphoria Therapeutics Inc. – Common Stock in a report issued on Tuesday, February 4th. HC Wainwright analyst J. Pantginis expects that the company will earn ($2.01) per share for the quarter. HC Wainwright has a “Buy” rating and a $21.00 price objective on the stock. HC Wainwright also issued estimates for Neuphoria Therapeutics Inc. – Common Stock’s Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($1.26) EPS, FY2025 earnings at ($1.56) EPS, Q1 2026 earnings at ($0.55) EPS, Q2 2026 earnings at ($0.61) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.42) EPS and FY2026 earnings at ($1.85) EPS.

Neuphoria Therapeutics Inc. – Common Stock Stock Up 1.2 %

Shares of Neuphoria Therapeutics Inc. – Common Stock stock opened at $5.15 on Thursday. Neuphoria Therapeutics Inc. – Common Stock has a 1-year low of $2.12 and a 1-year high of $16.08.

Neuphoria Therapeutics Inc. – Common Stock Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.